Menu

Broccoli Extract Lowers Blood Sugar in Diabetics

Concentrated sulforaphane, a chemical found in broccoli, reduced blood glucose levels in type 2 diabetes patients by 10 percent in a small trial.

Jun 15, 2017
Diana Kwon

PIXABAY, CONGERDESIGNA powder containing a highly concentrated dose of sulforaphane, a chemical found in broccoli sprouts, was able to lower blood sugar levels in individuals with type 2 diabetes, according to a study published Wednesday (June 14) in Science Translational Medicine.

“We’re very excited about the effects we’ve seen and are eager to bring the extract to patients,” study coauthor Anders Rosengren of the University of Gothenburg in Sweden tells New Scientist. “We saw a reduction of glucose of about 10 percent, which is sufficient to reduce complications in the eyes, kidneys, and blood.”

Rosengren and colleagues conducted a 12-week placebo-controlled trial in which 97 people with type 2 diabetes took either a highly concentrated sulforaphane powder (with a dose 100 times that found naturally in broccoli) or a placebo. Most participants continued to take metformin, a drug commonly used to lower blood sugar levels in diabetics.

The team discovered that their compound was able to reduce participant’s fasting blood glucose by 10 percent compared with those who took the placebo. The effects were strongest in individuals who were obese.

“More research is needed to see if this repurposed drug can be used to treat type 2 diabetes, as it was only tested in a small number of people and only helped a subset of those who are taking it,” Elizabeth Robertson, director of research at the charity Diabetes UK who was not involved in the study, tells New Scientist. “For now, we recommend that people continue with the treatment prescribed by their healthcare team.”

January 2019

Cannabis on Board

Research suggests ill effects of cannabinoids in the womb

Marketplace

Sponsored Product Updates

WIN a VIAFLO 96/384 to supercharge your microplate pipetting!
WIN a VIAFLO 96/384 to supercharge your microplate pipetting!
INTEGRA Biosciences is offering labs the chance to win a VIAFLO 96/384 pipette. Designed to simplify plate replication, plate reformatting or reservoir-to-plate transfers, the VIAFLO 96/384 allows labs without the space or budget for an expensive pipetting robot to increase the speed and throughput of routine tasks.
FORMULATRIX® digital PCR technology to be acquired by QIAGEN
FORMULATRIX® digital PCR technology to be acquired by QIAGEN
FORMULATRIX has announced that their digital PCR assets, including the CONSTELLATION® series of instruments, is being acquired by QIAGEN N.V. (NYSE: QGEN, Frankfurt Stock Exchange: QIA) for up to $260 million ($125 million upfront payment and $135 million of milestones).  QIAGEN has announced plans for a global launch in 2020 of a new series of digital PCR platforms that utilize the advanced dPCR technology developed by FORMULATRIX combined with QIAGEN’s expertise in assay development and automation.
Application of CRISPR/Cas to the Generation of Genetically Engineered Mice
Application of CRISPR/Cas to the Generation of Genetically Engineered Mice
With this application note from Taconic, learn about the power that the CRISPR/Cas system has to revolutionize the field of custom mouse model generation!
Translational Models of Obesity, Dysmetabolism, Diabetes, and Complications
Translational Models of Obesity, Dysmetabolism, Diabetes, and Complications
This webinar, from Crown Bioscience, presents a unique continuum of translational dysmetabolic platforms that more closely mimic human disease. Learn about using next-generation rodent and spontaneously diabetic non-human primate models to accurately model human-relevant disease progression and complications related to obesity and diabetes here!